MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection.

Sarah A E RupprechterDerek J SloanWilna OosthuyzenTill T BachmannAdam T HillKevin DhaliwalKate TempletonJoshua MatovuChristine Sekaggya-WiltshireJames W Dear

Published in: British journal of clinical pharmacology (2021)

In patients treated with anti-TB therapy, miR-122 and K18 correlated with ALT and increased with DILI. Further work should determine their diagnostic and prognostic utility in this global context-of-use.

Keyphrases

end stage renal disease
mycobacterium tuberculosis
newly diagnosed
ejection fraction
chronic kidney disease
cell proliferation
long non coding rna
peritoneal dialysis
prognostic factors
risk assessment
mesenchymal stem cells
patient reported
cell therapy